Generic NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE INN equivalents, drug patent expiry and freedom to operate

Sponsor	Phase
The Second Hospital of Nanjing Medical University	Phase 3
The Affiliated Hospital of Qingdao University	Phase 3
Jiangsu Provincial People's Hospital	Phase 3

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TREXIMET	Tablets	naproxen sodium; sumatriptan succinate	500 mg/85 mg	021926	1	2008-07-23

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm	SUMATRIPTAN AND NAPROXEN SODIUM	naproxen sodium; sumatriptan succinate	TABLET;ORAL	202803-001	Jul 20, 2018	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Rising	SUMATRIPTAN AND NAPROXEN SODIUM	naproxen sodium; sumatriptan succinate	TABLET;ORAL	090872-001	Sep 4, 2018	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Currax	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-002	May 14, 2015		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial			Y	⤷ Start Trial
Aurobindo Pharma Ltd	SUMATRIPTAN AND NAPROXEN SODIUM	naproxen sodium; sumatriptan succinate	TABLET;ORAL	207457-001	Feb 15, 2018	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Currax	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-001	Apr 15, 2008	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Currax	TREXIMET	naproxen sodium; sumatriptan succinate	TABLET;ORAL	021926-001	Apr 15, 2008	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Japan	2006515856		⤷ Start Trial
Israel	169041	MULTILAYER PHARMACEUTICAL TABLET COMPRISING NAPROXEN AND TRIPTAN	⤷ Start Trial
Australia	2003303631	Multilayer Dosage Forms Containing NSAIDs and Triptans	⤷ Start Trial
Mexico	PA05006954	FORMAS DE DOSIFICACION DE CAPAS MULTIPLES QUE CONTIENEN NSAIDS Y TRIPTANOS. (Multilayer Dosage Forms Containing NSAIDs and Triptans.)	⤷ Start Trial
Spain	2380827		⤷ Start Trial
World Intellectual Property Organization (WIPO)	2004060355		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1411900	1190013-1	Sweden	⤷ Start Trial	PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
1411900	300481	Netherlands	⤷ Start Trial	PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17901/0263-001 20101105
1411900	18/2011	Austria	⤷ Start Trial	PRODUCT NAME: NAPROXEN UND ESOMEPRAZOL SOWIE DEREN PHARMAZEUTISCH ANNEHMBARE SALZE; NAT. REGISTRATION NO/DATE: 1-29937 20110105; FIRST REGISTRATION: GB PL 17901/0263-0001 20101105
1411900	C300481	Netherlands	⤷ Start Trial	PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: PL 17901/0263-001 20101105
1411900	2011C/016	Belgium	⤷ Start Trial	PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214
0984957	SPC/GB11/013	United Kingdom	⤷ Start Trial	PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Last updated: April 25, 2026

Naproxen Sodium and Sumatriptan Succinate: Market Dynamics and Financial Trajectory

How big are the markets and what drives demand for naproxen sodium?

Naproxen sodium is an NSAID with long-standing OTC and prescription presence in the US and many ex-US markets. Demand is driven by (1) chronic and acute pain incidence, (2) OTC switching and shelf availability, (3) payer and guideline adherence for first-line musculoskeletal and inflammatory pain, and (4) price competition after originator-to-generics transitions.

Key demand drivers

Indication breadth: musculoskeletal pain (including arthritis-related pain), acute pain, and menstrual cramps; broad labeling supports steady utilization.
Route and formulation portfolio: immediate-release tablets and delayed-release variants (market-specific).
OTC penetration: persistent OTC purchasing supports baseline volume even when prescription volumes soften.
Safety and utilization controls: age, comorbidity, GI risk, and payer utilization management constrain upper-end growth even when underlying pain prevalence remains stable.

Competitive structure

Generics dominate price and share in most mature geographies.
Brand differentiation is limited: cost control and formulary access dominate buying behavior.
Retail concentration matters: OTC shelf access and pharmacy promotions influence unit sales.

How big are the markets and what drives demand for sumatriptan succinate?

Sumatriptan succinate is a triptan for migraine. Demand is driven by (1) migraine prevalence, (2) breakthrough-like acute therapy usage patterns, (3) prescriber and payer preferences for fast onset profiles, and (4) substitution by other triptans or non-triptan acute migraine options (notably CGRP-pathway agents and gepants in markets where uptake is high).

Key demand drivers

Acute migraine frequency: patient-level recurrence drives repeat purchases.
Formulation migration: tablets versus faster-onset formulations can shift share within the class by patient preference and clinical fit.
Formulary positioning: payer step therapy and preferred-drug lists shape volume.
Competitive pressure from newer classes: CGRP agents and gepants reduce growth headroom for older triptans in some markets, though triptans still retain substantial share in many formularies due to lower cost and clinical familiarity.

Competitive structure

Strong generics position post-expiration drives pricing and margin compression.
Class-level competition remains active: other triptans compete on onset, tolerability, and device/formulation convenience.
Substitution risk rises with newer acute migraine options where payers prefer those products.

What is the financial trajectory for each product in the typical life-cycle phase?

Naproxen sodium: pricing pressure, steady volume, and low margin uplift

For naproxen sodium, the mature NSAID profile points to:

Near-term revenue stability from volume: pain prevalence and OTC purchasing sustain units.
Ongoing ASP compression from multi-source competition: generics keep net price from expanding.
Limited upside from new entrants: incremental formulation improvements may shift share marginally, but rarely restart meaningful premium pricing.
Revenue growth typically tracks inflation and minor share movements, not disease-growth alone.

Trajectory pattern (mature OTC/Generic NSAID)

Revenue: stable-to-slightly declining in real terms in highly saturated markets due to pricing erosion.
Margin: low and pressured, with gross margin dependent on distribution model and promotional intensity.
Key risk: OTC supply competition and periodic price resets can depress unit economics even if unit demand stays resilient.

Sumatriptan succinate: revenue plateau with periodic demand shocks

For sumatriptan succinate, the financial profile reflects:

Revenue plateau behavior: migraine is chronic and recurrent, but older triptans face structural substitution from newer acute migraine classes in some geographies.
Price compression: generic saturation keeps net pricing from moving upward.
Resilience from cost advantage: when payers tighten budgets, older generic triptans can regain relative share versus newer, higher-cost options.
Rebound potential: policy-driven coverage changes or payer formulary read-through can shift share between older triptans and alternatives.

Trajectory pattern (mature generic acute migraine)

Revenue: typically flat to declining in real terms, with occasional stabilization when newer competitors face access or tolerability constraints.
Margin: structurally constrained by generic competition.
Key risk: accelerated uptake of CGRP/gepant-based acute therapy in geographies with strong guideline adoption and payer preference.

How do US market dynamics specifically affect revenue and share?

Naproxen sodium in the US

OTC + generics: the US market structure favors unit-driven economics rather than brand premium.
Retail competition: pharmacy chains and mass retailers can drive frequent price adjustments.
Payer dynamics matter less: OTC demand reduces dependency on prescription reimbursement volatility, though prescription volumes still contribute.

Implication for financial trajectory

Revenue is most sensitive to:
- OTC pricing and promotions,
- retailer ordering patterns,
- competitive intensity among generic suppliers.

Sumatriptan succinate in the US

Prescription dependence: unlike OTC-leaning NSAIDs, triptans are more sensitive to reimbursement, prior authorization patterns, and formulary preferences.
Shift risk: increased utilization of non-triptan acute migraine medicines can reduce prescription demand for older triptans.
Generic shelf stability: multi-source availability limits sudden share collapses but also caps price-led growth.

Implication for financial trajectory

Revenue is most sensitive to:
- formulary access,
- patient switching between acute categories,
- payer step-therapy requirements.

What do competitive substitution dynamics look like across the two drugs?

Naproxen sodium substitution

Substitution is primarily within NSAIDs and across OTC brands.
Competitive differentiation is limited; price and pack availability dominate.
Safety messaging and prescriber habits influence which NSAID patients choose, but generics reduce long-term differentiation.

Sumatriptan succinate substitution

Substitution occurs at the acute migraine therapy level:
- older triptans versus newer acute migraine classes,
- between different triptans by formulation and onset,
- via patient and payer preference in formulary tiers.
As newer agents gain access, triptan growth typically slows or declines.

What are the financial “levers” management would track (and how each product responds)?

1) Net price (ASP/WAC)

Naproxen sodium: net price drifts downward across generic cohorts; revenue growth often needs volume to offset.
Sumatriptan succinate: net price is constrained by generic mix; any improvement is usually offset by substitution.

2) Volume (units and scripts)

Naproxen sodium: volume is resilient due to OTC availability and broad pain indications.
Sumatriptan succinate: volume depends on migraine diagnosis prevalence, adherence, and acute treatment selection.

3) Channel mix (OTC versus Rx)

Naproxen sodium: OTC mix acts as a revenue stabilizer during prescription volatility.
Sumatriptan succinate: Rx mix is exposed to payer policy and formulary tiers.

4) Forecast sensitivity to payer access

Naproxen sodium: less exposed than triptans.
Sumatriptan succinate: highly exposed; policy and coverage rules can reallocate share quickly.

5) Competitive intensity and pack economics

Naproxen sodium: high intensity from multiple generic manufacturers and OTC pack formats.
Sumatriptan succinate: high intensity from multi-source generics plus therapeutic-class competition.

How should investors and R&D strategists interpret “trajectory” for these assets?

Naproxen sodium

Base case: stable demand with persistent pricing pressure.
Financial character: mature, commodity-like revenue streams where distribution and cost competitiveness determine profitability rather than premium innovation.
Strategic focus: reformulation for dosing convenience or lifecycle extension, if available in the company’s portfolio and if differentiation can preserve share without premium pricing.

Sumatriptan succinate

Base case: plateau under generic competition with substitution pressure from newer acute migraine therapies.
Financial character: demand recurrence supports durability, but new-class uptake can flatten growth.
Strategic focus: lifecycle management, formulation improvements (if any exist), and payer-aligned contracting to defend access.

Key Takeaways

Both products sit in mature, generic-dominated segments, so financial trajectory is driven more by volume and channel access than by price.
Naproxen sodium shows greater resilience from OTC breadth and indication coverage, but net price remains structurally pressured.
Sumatriptan succinate shows recurrence-driven stability but faces therapeutic substitution risk as newer acute migraine options expand coverage.
In both cases, payer/formulary positioning matters more for sumatriptan than for naproxen sodium, which is supported by OTC demand.

FAQs

1) Is naproxen sodium likely to grow faster than sumatriptan?

Naproxen sodium typically has stronger baseline resilience due to OTC availability and broad indication coverage, while sumatriptan faces more direct substitution from newer acute migraine categories.

2) What most constrains profitability for these drugs?

Generic competition constrains net price, and mature utilization patterns limit margin uplift. For sumatriptan, payer access and formulary tiers add additional constraints.

3) Does OTC availability change the risk profile for naproxen?

Yes. OTC demand reduces dependence on prescription coverage and formulary access, making revenue less sensitive to payer policy swings.

4) What is the biggest long-run substitution threat to sumatriptan?

Acute migraine therapies from newer classes (including CGRP-pathway and gepant options where widely adopted and preferred) can shift patient selection away from older triptans.

5) What “leading indicators” best signal near-term trajectory?

For naproxen: OTC and retail pack price/promotional environment and unit movement. For sumatriptan: script trends, formulary tier changes, and substitution patterns within acute migraine therapy.

References

[1] FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] IMS Institute / IQVIA reports on generic market dynamics and price trends (series pages). https://www.iqvia.com/insights/the-iqvia-institute
[3] WHO ATC/DDD Index. https://www.whocc.no/atc_ddd_index/
[4] American Migraine Foundation: Migraine treatment overview (acute therapy context). https://americanmigrainefoundation.org/
[5] FDA consumer information on NSAIDs (safety and labeling context). https://www.fda.gov/

International Patents:	16
US Patents:	1
Tradenames:	2
Applicants:	4
NDAs:	4
Finished Product Suppliers / Packagers:	5
Clinical Trials:	11
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE
DailyMed Link:	NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE at DailyMed

Drug Class	Nonsteroidal Anti-inflammatory Drug Serotonin-1b and Serotonin-1d Receptor Agonist
Mechanism of Action	Cyclooxygenase Inhibitors Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists

Summary for NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

Recent Clinical Trials for NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

Pharmacology for NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

Anatomical Therapeutic Chemical (ATC) Classes for NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

Paragraph IV (Patent) Challenges for NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE